SG11202102111SA - Cell-based clostridal neurotoxin assays - Google Patents
Cell-based clostridal neurotoxin assaysInfo
- Publication number
- SG11202102111SA SG11202102111SA SG11202102111SA SG11202102111SA SG11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA
- Authority
- SG
- Singapore
- Prior art keywords
- clostridal
- cell
- neurotoxin
- assays
- neurotoxin assays
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201815870 | 2018-09-28 | ||
PCT/GB2019/052734 WO2020065338A1 (en) | 2018-09-28 | 2019-09-27 | Cell-based clostridal neurotoxin assays |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102111SA true SG11202102111SA (en) | 2021-04-29 |
Family
ID=68136432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102111SA SG11202102111SA (en) | 2018-09-28 | 2019-09-27 | Cell-based clostridal neurotoxin assays |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220357314A1 (en) |
EP (1) | EP3856923A1 (en) |
JP (1) | JP2022512565A (en) |
KR (1) | KR20210098436A (en) |
CN (1) | CN113015812A (en) |
AU (1) | AU2019350528A1 (en) |
BR (1) | BR112021005774A2 (en) |
CA (1) | CA3111674A1 (en) |
EA (1) | EA202190892A1 (en) |
MX (1) | MX2021002726A (en) |
SG (1) | SG11202102111SA (en) |
WO (1) | WO2020065338A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE061429T2 (en) * | 2016-07-08 | 2023-06-28 | Childrens Medical Center | A novel botulinum neurotoxin and its derivatives |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
EP2264052A3 (en) | 1999-08-25 | 2011-04-20 | Allergan, Inc. | Activatable recombinant neurotoxins |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US7183066B2 (en) * | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
DE102004043009A1 (en) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transport protein for introducing chemical compounds into nerve cells |
DE102005019302A1 (en) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier for targeting nerve cells |
JP5764550B2 (en) | 2009-04-14 | 2015-08-19 | エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド | Genetically engineered botulinum neurotoxin |
WO2012047325A2 (en) * | 2010-06-11 | 2012-04-12 | Synaptic Research, Llc | N-end rule protease activity indication methods and uses thereof |
US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
CN103958747B (en) * | 2011-09-29 | 2017-03-01 | 塞尔斯纳普有限责任公司 | Compositionss for toxigenicity test and method |
AU2013331771B2 (en) * | 2012-10-16 | 2018-08-02 | Merz Pharma Gmbh & Co. Kgaa | Cellular test systems for the determination of the biological activities of neurotoxin polypeptides |
US10634683B2 (en) * | 2014-11-21 | 2020-04-28 | Merz Pharma Gmbh & Co. Kgaa | Methods for the determination of the biological activities of neurotoxin polypeptides |
EP3447120B1 (en) * | 2016-05-24 | 2021-06-23 | Nippon Telegraph And Telephone Corporation | Three-dimensional thin film structure having microparticles enclosed therein and method for manufacturing same |
HUE061429T2 (en) | 2016-07-08 | 2023-06-28 | Childrens Medical Center | A novel botulinum neurotoxin and its derivatives |
-
2019
- 2019-09-27 SG SG11202102111SA patent/SG11202102111SA/en unknown
- 2019-09-27 EA EA202190892A patent/EA202190892A1/en unknown
- 2019-09-27 BR BR112021005774A patent/BR112021005774A2/en unknown
- 2019-09-27 US US17/278,465 patent/US20220357314A1/en active Pending
- 2019-09-27 WO PCT/GB2019/052734 patent/WO2020065338A1/en active Application Filing
- 2019-09-27 MX MX2021002726A patent/MX2021002726A/en unknown
- 2019-09-27 CA CA3111674A patent/CA3111674A1/en active Pending
- 2019-09-27 AU AU2019350528A patent/AU2019350528A1/en active Pending
- 2019-09-27 CN CN201980063740.0A patent/CN113015812A/en active Pending
- 2019-09-27 KR KR1020217012648A patent/KR20210098436A/en not_active Application Discontinuation
- 2019-09-27 JP JP2021517583A patent/JP2022512565A/en active Pending
- 2019-09-27 EP EP19782681.1A patent/EP3856923A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210098436A (en) | 2021-08-10 |
JP2022512565A (en) | 2022-02-07 |
AU2019350528A1 (en) | 2021-04-15 |
CN113015812A (en) | 2021-06-22 |
CA3111674A1 (en) | 2020-04-02 |
MX2021002726A (en) | 2021-07-16 |
EA202190892A1 (en) | 2021-07-05 |
WO2020065338A1 (en) | 2020-04-02 |
BR112021005774A2 (en) | 2021-07-06 |
EP3856923A1 (en) | 2021-08-04 |
US20220357314A1 (en) | 2022-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3662259A4 (en) | Colorimetric assays | |
EP3212757A4 (en) | Microfluidic device for cell-based assays | |
EP3602218A4 (en) | Predictive integrity analysis | |
IL277687A (en) | Colocalization-by-linkage sandwich assays | |
IL266857A (en) | Antibody assay | |
GB201807409D0 (en) | Assay | |
GB201900893D0 (en) | Cell contamination assay | |
GB201819187D0 (en) | Assay | |
GB2579810B (en) | Assay Analysis | |
SG11202102111SA (en) | Cell-based clostridal neurotoxin assays | |
GB201820863D0 (en) | Screening assay | |
IL287629A (en) | Assays | |
GB201815278D0 (en) | Assay | |
GB201809338D0 (en) | Cell contamination assay | |
GB201809337D0 (en) | Cell contamination assay | |
GB201809336D0 (en) | Cell contamination assay | |
GB201801036D0 (en) | Cell contamination assay | |
GB201801035D0 (en) | Cell Contamination Assay | |
GB201801034D0 (en) | Cell contamination assay | |
GB201914959D0 (en) | Assay | |
GB201911397D0 (en) | Assay | |
GB201911182D0 (en) | Assay | |
GB201910477D0 (en) | Assay | |
GB201817024D0 (en) | Serum biomarkers | |
GB201816764D0 (en) | Serum biomarkers |